NAVIGATOR: Tezepelumab Could Transform Severe Uncontrolled Asthma Care

AstraZeneca PLC and Amgen, Inc.’s jointly developed MAb tezepelumab has met the primary endpoint in top-line results from the Phase III NAVIGATOR study in patients with severe uncontrolled asthma, and there are expectations it could become a first-in-class agent – a thymic stromal lymphopoietin (TSLP) blocker – for this still poorly served category of patients. 

When tezepelumab was added to the standard-of-care in a broad population of severe uncontrolled asthmatics in NAVIGATOR, the human monoclonal antibody was associated with a significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) over 52 weeks, compared with